BioNotebook: Six deals and a name change; Spectrum/CASI, Five Prime/GSK and more

CASI will develop Spectrum drugs in China; GlaxoSmithKline options Five Prime candidates; MedGenesis licenses technology to Pfizer; Soon-Shiong's NantBioScience initiates cancer collaboration; ImaginAb expands imaging agent pipeline; Akashi acquires DMD drug; and Oxygen changes name to Tenax.

CASI will develop Spectrum drugs in China; GlaxoSmithKline options Five Prime candidates; MedGenesis licenses technology to Pfizer; Soon-Shiong's NantBioScience initiates cancer collaboration; ImaginAb expands imaging agent pipeline; Akashi acquires DMD drug; and Oxygen changes name to Tenax.

Spectrum takes a stake in CASI in China deal

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category